Jean-Charles Soria to Risk Factors
This is a "connection" page, showing publications Jean-Charles Soria has written about Risk Factors.
Connection Strength
0.056
-
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer. 2011 Oct; 47(15):2249-55.
Score: 0.014
-
[Biomarkers of carcinogenesis of the upper and lower airway epithelium and the role of chemoprevention]. Bull Cancer. 2001 Apr; 88(4):351-61.
Score: 0.007
-
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discov. 2021 02; 11(2):233-236.
Score: 0.007
-
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. Eur J Cancer. 2018 03; 92:1-10.
Score: 0.006
-
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018 03; 91:21-29.
Score: 0.006
-
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017 12; 87:122-130.
Score: 0.006
-
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer. 2017 10; 84:202-211.
Score: 0.005
-
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017 10; 84:212-218.
Score: 0.005